Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Sugawara, SSSugawaraLee, J-SJ-SLeeKang, J-HJ-HKangKim, H RH RKimInui, NNInuiHida, TTHidaLee, K HK HLeeYoshida, TTYoshidaTanaka, HHTanakaYang, C-TC-TYangNishio, MMNishioOhe, YYOheTamura, TTTamuraYamamoto, NNYamamotoCHONG-JEN YUAkamatsu, HHAkamatsuNamba, YYNambaSumiyoshi, NNSumiyoshiNakagawa, KKNakagawa2023-11-082023-11-082021-0909237534https://scholars.lib.ntu.edu.tw/handle/123456789/636927This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC).enNSCLC; bevacizumab; nivolumab[SDGs]SDG3Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerjournal article10.1016/j.annonc.2021.06.004341392722-s2.0-85110460352https://api.elsevier.com/content/abstract/scopus_id/85110460352